IL6 and chronic obstructive pulmonary disease: The results demonstrate that YPFS significantly enhances oxidase activity while decreasing the levels of TNF-a, IL-6, TGF-β1, and phosphorylated-Smad2 (p-smad2) in YPFS-treated COPD rats compared to untreated COPD rats.